1-11 of 11
John Desjarlais
Close
Sort by
Journal Articles

Regulatory T Cell Selective IL-2-Fc Fusion Proteins for the Treatment of Autoimmune Diseases

Rajat Varma, PhD, Ke Liu, PhD, Kendra Avery, PhD, Rumana Rashid, PhD, Suzanne Schubbert, PhD, Irene Leung, PhD, Christine Bonzon, PhD, Liz Bogaert, PhD, John Desjarlais, Matthew J. Bernett
Journal: Blood
Blood (2018) 132 (Supplement 1): 3709.
https://doi.org/10.1182/blood-2018-99-117622
Published: 2018
Journal Articles

Preclinical Characterization of AMG 424, a Novel Humanized T Cell-Recruiting Bispecific Anti-CD3/CD38 Antibody

Christina de Zafra, Mercedesz Balazs, Flordeliza Fajardo, Lingming Liang, Wendy Zhong, Anja Henn, Matthew J. Bernett, Gregory Moore, Umesh Muchhal, Dwight Winters, Brendon Frank, Kevin Cook, Josh Pearson, Murad Melhem, Vladimir Petrovic, Robert J. Pelham, Matthias Friedrich, Hong Tan, Gordon Moody, Jenitte Stevens, John Desjarlais, Angela Coxon, Olivier Nolan-Stevaux
Journal: Blood
Blood (2017) 130 (Supplement 1): 500.
https://doi.org/10.1182/blood.V130.Suppl_1.500.500
Published: 2017
Journal Articles

Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 × Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma

Gregory L. Moore, PhD, Sung-Hyung Lee, PhD, Suzanne Schubbert, PhD, Yvonne Miranda, MS, Rumana Rashid, PhD, Erik Pong, BS, Sheryl Phung, MS, Emily W. Chan, BS, Hsing Chen, MS, Nancy Endo, BS, Maria C. Ardila, BS, Matthew J. Bernett, PhD, Seung Chu, PhD, Irene W.L. Leung, PhD, Umesh Muchhal, PhD, Christine Bonzon, PhD, David E Szymkowski, PhD, John Desjarlais, PhD
Journal: Blood
Blood (2015) 126 (23): 1798.
https://doi.org/10.1182/blood.V126.23.1798.1798
Published: 2015
Journal Articles

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Stefanie Derer, PhD, Pia Glorius, PhD, Martin Schlaeth, Stefan Lohse, PhD, Umesh Muchhal, Ph.D., John Desjarlais, Andreas Humpe, MD, Thomas Valerius, MD, Matthias Peipp, PhD
Journal: Blood
Blood (2013) 122 (21): 3466.
https://doi.org/10.1182/blood.V122.21.3466.3466
Published: 2013
Journal Articles

Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation

Sun-Young Kong, MD, PhD, Sabikun Nahar, Xian-Feng Li, Weihua Song, MD, Yiguo Hu, Umesh Muchhal, John Desjarlais, Paul Richardson, M.D., Ph.D., Nikhil C. Munshi, MD, Kenneth C. Anderson, Yu-Tzu Tai, PhD
Journal: Blood
Blood (2010) 116 (21): 4064.
https://doi.org/10.1182/blood.V116.21.4064.4064
Published: 2010
Journal Articles

CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.

Farrukh Awan, MD, MS, Rosa Lapalombella, PhD, Rossana Trotta, PhD, Jonathan P Butchar, Ph.D., Bo Yu, Don Benson, MD, PhD, Carolyn Cheney, Xiaokui Mo, Amy Lehman, Jeffrey Alan Jones, MD, MPH, Joseph M Flynn, David Jarjoura, Robert A. Baiocchi, MD, PhD, John Desjarlais, Susheela Tridandapani, Ph.D., Michael A. Caligiuri, M.D., Natarajan Muthusamy, PhD, John C. Byrd
Journal: Blood
Blood (2009) 114 (22): 3725.
https://doi.org/10.1182/blood.V114.22.3725.3725
Published: 2009
Journal Articles

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Umesh Muchhal, Ph.D., Xian-Feng Li, MS, Sabikun Nahar, B.S., Weihua Song, MD, Holly Horton, Ph.D, Hanh Nguyen, Sher Karki, John Desjarlais, Nikhil C. Munshi, MD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 609.
https://doi.org/10.1182/blood.V114.22.609.609
Published: 2009
Journal Articles

An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

Eugene A. Zhukovsky, PhD, Holly Horton, Ph.D, Matthias Peipp, PhD, Erik Pong, BS, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Seung Chu, PhD, Roland Repp, MD, John Desjarlais, PhD
Journal: Blood
Blood (2008) 112 (11): 881.
https://doi.org/10.1182/blood.V112.11.881.881
Published: 2008
Journal Articles

XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia.

Eugene Zhukovsky, PhD, Seung Chu, PhD, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Erik Pong, BS, Matthias Peipp, PhD, Roland Repp, MD, John Desjarlais, PhD
Journal: Blood
Blood (2007) 110 (11): 2335.
https://doi.org/10.1182/blood.V110.11.2335.2335
Published: 2007
Journal Articles

Pre-Clinical Activity of a Novel FcγRIIIa Engineered CD19 Monoclonal Antibody in B Cell Chronic Lymphocytic Leukemia and Acute Lymphoblastic Leukemia.

Julie M. Roda, Rosa Lapalombella, Robert Baiocchi, Eugene Zhukocsky, John Desjarlais, Natarajan Muthusamy, John C. Byrd
Journal: Blood
Blood (2007) 110 (11): 2351.
https://doi.org/10.1182/blood.V110.11.2351.2351
Published: 2007
Journal Articles

Fc Engineered Anti-CD19 Monoclonal Antibodies with Enhanced In Vitro Efficacy Against Multiple Lymphoma Cell Lines.

Eugene A. Zhukovsky, PhD, Seung Chu, Ph.D., Matthew Bernett, Ph.D., Philip Hammond, Ph.D., Sher Karki, Ph.D., Wei Dang, Ph.D., Collin Edler, M.S., Nephi Polder, B.S., Cheryl Chan, B.S., Jonathan Jacinto, B.S., John Desjarlais, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 4747.
https://doi.org/10.1182/blood.V108.11.4747.4747
Published: 2006